URD12: A urea derivative with marked antitumor activities

Area of Science:

• Pharmacology
• Oncology
• Medicinal Chemistry

Background:

• Urea derivatives are extensively utilized in biological and medical applications.
• The substituted urea derivative URD12 has shown preliminary cytotoxic effects against leukemia and carcinoma cell lines.

Purpose of the Study:

• To investigate the bioactivity and antitumor potential of the urea derivative URD12.
• To evaluate URD12 as a potential new antitumor drug candidate through in vitro and in vivo studies.

Main Methods:

• Preparation and cytotoxicity evaluation of URD12 against multiple human cancer cell lines (BGC-823, MGC-803, SMMC-7721, HepG2) using MTT assays.
• In vivo antitumor activity assessment in mice bearing H22 hepatocellular carcinoma.
• Analysis of organ coefficients (weight, spleen, thymus) to understand cytotoxic mechanisms and potential side effects.

Main Results:

• URD12 exhibited significant inhibition of tumor cell growth in vitro across all tested human cancer cell lines.
• In vivo studies confirmed URD12's efficacy in suppressing the growth of H22 mouse hepatocellular carcinoma.
• URD12 did not adversely affect the weight, spleen, or thymus coefficients in tumor-bearing mice, indicating a lack of evident immunosuppression.

Conclusions:

• The substituted urea derivative URD12 demonstrates potent in vitro and in vivo antitumor activity.
• URD12 represents a promising candidate for a new antitumor agent due to its efficacy and lack of significant immunosuppressive effects.